Nkarta reports Q2 EPS (31c), consensus (35c)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 12 2025
0mins
Should l Buy NKTX?
Focus on Clinical Trials: Nkarta's CEO, Paul Hastings, emphasizes the company's commitment to executing clinical trials for NK cell therapy aimed at treating autoimmune diseases, highlighting the importance of their new clinical team members with rheumatology expertise.
Expertise in Autoimmune Treatment: The addition of Dr. Rose, a seasoned rheumatologist and immunologist, is expected to enhance Nkarta's NKX019 clinical trial programs by leveraging his extensive experience in drug development within the autoimmune sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTX
Wall Street analysts forecast NKTX stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.130
Low
10.00
Averages
12.33
High
16.00
Current: 2.130
Low
10.00
Averages
12.33
High
16.00
About NKTX
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nkarta Q4 Earnings Miss Expectations
- Earnings Performance: Nkarta reported a Q4 GAAP EPS of -$0.37, missing the expected -$0.32, indicating challenges in profitability that could affect investor confidence moving forward.
- Cash Position: As of December 31, 2025, Nkarta had cash, cash equivalents, restricted cash, and marketable securities totaling $295.1 million, suggesting a reasonable liquidity cushion, but future capital efficiency will be crucial.
- Market Reaction: The earnings miss may put downward pressure on Nkarta's stock price, prompting investors to closely monitor subsequent financial performance and management's strategic responses.
- Future Outlook: Despite the current disappointing financial data, Nkarta must develop effective strategies to enhance profitability and strengthen its competitive position, particularly in the rapidly evolving biopharmaceutical sector.
See More
NKARTA REPORTS Q4 NET LOSS OF USD 27.408 MILLION
- Financial Performance: The company reported a net income of USD 27.408 million.
- Quarterly Results: This figure reflects the financial results for the recent quarter.
See More
NKARTA Reports Q4 Basic EPS of USD -0.37
Market Overview: The article discusses the current state of the market, highlighting key trends and movements in various sectors.
Economic Indicators: It emphasizes the importance of recent economic indicators that are influencing market performance and investor sentiment.
Investment Strategies: The piece outlines potential investment strategies that could be beneficial in the current economic climate.
Future Outlook: It concludes with predictions about future market developments and factors that could impact growth.
See More
Nkarta Files $350M Mixed-Securities Offering to Fund Growth
- Funding Initiative: Nkarta has filed a $350 million mixed-securities registration with the SEC, planning to sell up to $100 million in common stock through an ATM deal with Stifel, Nicolaus & Company to support its funding needs.
- Commission Structure: Stifel may earn up to a 3% commission on the shares sold, which will impact Nkarta's financing costs while providing Stifel with an additional revenue stream.
- Use of Proceeds: The net proceeds from this offering will be allocated to R&D, manufacturing, working capital, capital expenditures, and general corporate purposes, including strategic investments aimed at enhancing the company's market competitiveness and innovation capabilities.
- Future Sales Opportunities: Any unsold portion of the $100 million will be available for future sales under the base prospectus, providing Nkarta with flexible financing options to adapt to changing market demands.
See More
ImmunityBio Shares Triple in Three Weeks, Short-Sellers Face $500 Million Loss
- Price Surge: ImmunityBio's stock price has tripled over three weeks, closing at $6.92 on Wednesday with a 6.79% increase, indicating strong market interest in its immunotherapy developments, potentially attracting more investors.
- Volume Spike: Trading volume reached 93.5 million shares on Wednesday, about 357% above the three-month average of 20.5 million shares, signaling a significant rise in investor attention that could lead to further price volatility.
- Short-Seller Losses: With 35% of the public float held short, short-sellers now face nearly $500 million in paper losses, reflecting optimistic market sentiment towards ImmunityBio's future developments, which may prompt short-covering to mitigate losses.
- Market Reaction: Although there was no specific news driving the price increase, the actions of short-sellers covering their positions combined with recent positive developments have contributed to the stock's rise, showcasing ongoing interest in the biotechnology sector.
See More
Nkarta (NKTX) Participates in Evercore 8th Annual Healthcare Conference to Showcase NK Cell Therapy Progress
- Conference Participation: Nkarta will participate in the Evercore 8th Annual Healthcare Conference on December 4 in Miami, showcasing its progress in NK cell therapies for autoimmune diseases, which is expected to attract investor and industry attention.
- Live Webcast: The event is scheduled for 10:50 a.m. ET and will be simultaneously webcast on Nkarta's investor section of its website, allowing global investors to access real-time information.
- Replay Availability: Following the conference, a replay will be archived on Nkarta's website for approximately 90 days, ensuring that investors who cannot attend live can still access relevant information, thereby enhancing the company's transparency.
- Company Background: Nkarta focuses on developing allogeneic, off-the-shelf NK cell therapies, combining cell expansion and cryopreservation platforms to provide deep therapeutic activity intended for broad outpatient access, demonstrating its innovative potential in the biopharmaceutical sector.
See More
Nkarta Q4 Earnings Miss Expectations
- Earnings Performance: Nkarta reported a Q4 GAAP EPS of -$0.37, missing the expected -$0.32, indicating challenges in profitability that could affect investor confidence moving forward.
- Cash Position: As of December 31, 2025, Nkarta had cash, cash equivalents, restricted cash, and marketable securities totaling $295.1 million, suggesting a reasonable liquidity cushion, but future capital efficiency will be crucial.
- Market Reaction: The earnings miss may put downward pressure on Nkarta's stock price, prompting investors to closely monitor subsequent financial performance and management's strategic responses.
- Future Outlook: Despite the current disappointing financial data, Nkarta must develop effective strategies to enhance profitability and strengthen its competitive position, particularly in the rapidly evolving biopharmaceutical sector.
See More
NKARTA REPORTS Q4 NET LOSS OF USD 27.408 MILLION
- Financial Performance: The company reported a net income of USD 27.408 million.
- Quarterly Results: This figure reflects the financial results for the recent quarter.
See More
NKARTA Reports Q4 Basic EPS of USD -0.37
Market Overview: The article discusses the current state of the market, highlighting key trends and movements in various sectors.
Economic Indicators: It emphasizes the importance of recent economic indicators that are influencing market performance and investor sentiment.
Investment Strategies: The piece outlines potential investment strategies that could be beneficial in the current economic climate.
Future Outlook: It concludes with predictions about future market developments and factors that could impact growth.
See More
Nkarta Files $350M Mixed-Securities Offering to Fund Growth
- Funding Initiative: Nkarta has filed a $350 million mixed-securities registration with the SEC, planning to sell up to $100 million in common stock through an ATM deal with Stifel, Nicolaus & Company to support its funding needs.
- Commission Structure: Stifel may earn up to a 3% commission on the shares sold, which will impact Nkarta's financing costs while providing Stifel with an additional revenue stream.
- Use of Proceeds: The net proceeds from this offering will be allocated to R&D, manufacturing, working capital, capital expenditures, and general corporate purposes, including strategic investments aimed at enhancing the company's market competitiveness and innovation capabilities.
- Future Sales Opportunities: Any unsold portion of the $100 million will be available for future sales under the base prospectus, providing Nkarta with flexible financing options to adapt to changing market demands.
See More
ImmunityBio Shares Triple in Three Weeks, Short-Sellers Face $500 Million Loss
- Price Surge: ImmunityBio's stock price has tripled over three weeks, closing at $6.92 on Wednesday with a 6.79% increase, indicating strong market interest in its immunotherapy developments, potentially attracting more investors.
- Volume Spike: Trading volume reached 93.5 million shares on Wednesday, about 357% above the three-month average of 20.5 million shares, signaling a significant rise in investor attention that could lead to further price volatility.
- Short-Seller Losses: With 35% of the public float held short, short-sellers now face nearly $500 million in paper losses, reflecting optimistic market sentiment towards ImmunityBio's future developments, which may prompt short-covering to mitigate losses.
- Market Reaction: Although there was no specific news driving the price increase, the actions of short-sellers covering their positions combined with recent positive developments have contributed to the stock's rise, showcasing ongoing interest in the biotechnology sector.
See More
Nkarta (NKTX) Participates in Evercore 8th Annual Healthcare Conference to Showcase NK Cell Therapy Progress
- Conference Participation: Nkarta will participate in the Evercore 8th Annual Healthcare Conference on December 4 in Miami, showcasing its progress in NK cell therapies for autoimmune diseases, which is expected to attract investor and industry attention.
- Live Webcast: The event is scheduled for 10:50 a.m. ET and will be simultaneously webcast on Nkarta's investor section of its website, allowing global investors to access real-time information.
- Replay Availability: Following the conference, a replay will be archived on Nkarta's website for approximately 90 days, ensuring that investors who cannot attend live can still access relevant information, thereby enhancing the company's transparency.
- Company Background: Nkarta focuses on developing allogeneic, off-the-shelf NK cell therapies, combining cell expansion and cryopreservation platforms to provide deep therapeutic activity intended for broad outpatient access, demonstrating its innovative potential in the biopharmaceutical sector.
See More
